Gemtuzumab and blood lactate dehydrogenase increased Patient Reports February 13, 2012

Gemtuzumab Side Effects Report #4978389-4
Gemtuzumab side effect was reported by a Consumer or non-health professional from ITALY on Apr 07, 2006. Male patient, 40 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood lactate dehydrogenase increased, febrile neutropenia, portal vein thrombosis. Gemtuzumab dosage: unknown. Patient was hospitalized. Patient recovered.

Gemtuzumab Side Effects Report #4979712-7
Gemtuzumab side effect was reported by a Consumer or non-health professional from ITALY on Apr 07, 2006. Male patient, 40 years of age, was diagnosed with acute promyelocytic leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blood lactate dehydrogenase increased, febrile neutropenia, portal vein thrombosis. Gemtuzumab dosage: unknown. Patient was hospitalized. Patient recovered.

Gemtuzumab Side Effects Report #4927935-5
Gemtuzumab side effect was reported by a Consumer or non-health professional from DENMARK on Feb 10, 2006. Male patient was diagnosed with acute myeloid leukaemia recurrent and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: blood creatine phosphokinase increased, blood lactate dehydrogenase increased, haemoglobin decreased, haemolysis, infection , neutrophil count increased, thrombocytopenia. Gemtuzumab dosage: 3.8 MG 1X PER 1 DASY, INTRAVENOUS. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN. Patient recovered.

Gemtuzumab Side Effects Report #5210315-5
Gemtuzumab side effect was reported by a Consumer or non-health professional from ITALY on Jan 05, 2007. Male patient, 83 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: blood lactate dehydrogenase increased, colitis ischaemic, disease progression, infection , intestinal haemorrhage, respiratory distress. Gemtuzumab dosage: 5 MG; SEE IMAGE. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN, GLAZIDIM, TRIDECANAMINE, LEVOFLOXACIN, VORICONAZOLE, MEROPENEM, CYTARABINE. Patient died.


Gemtuzumab Side Effects Report #5191242-9
Gemtuzumab side effect was reported by a Consumer or non-health professional from ITALY on Dec 05, 2006. Male patient, 83 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: blood lactate dehydrogenase increased, colitis ischaemic, intestinal haemorrhage. Gemtuzumab dosage: unknown. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN, GLAZIDIM, TRIDECANAMINE, LEVOFLOXACIN. Patient recovered.

Gemtuzumab Side Effects Report #5097855-7
Gemtuzumab side effect was reported by a Consumer or non-health professional from GERMANY on Aug 25, 2006. Female patient, 66 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, blood calcium decreased, blood chloride increased, blood fibrinogen increased, blood lactate dehydrogenase increased, blood sodium increased. Gemtuzumab dosage: 10.5 MG INTRAVENOUS. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN, CYTARABINE. Patient was hospitalized. Patient died.

Gemtuzumab Side Effects Report #5097882-X
Gemtuzumab side effect was reported by a Consumer or non-health professional from GERMANY on Aug 25, 2006. Female patient, 66 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, aspartate aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, blood calcium decreased, blood chloride increased, blood fibrinogen increased, blood lactate dehydrogenase increased, blood sodium increased. Gemtuzumab dosage: 10.5 MG INTRAVENOUS. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN, CYTARABINE. Patient died.

Gemtuzumab Side Effects Report #4911217-1
Gemtuzumab side effect was reported by a Consumer or non-health professional from AUSTRIA on Jan 22, 2004. Male patient, 66 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, ascites, aspartate aminotransferase increased, blood lactate dehydrogenase increased, dyspnoea, gamma-glutamyltransferase increased, hepatic steatosis, hypokalaemia, liver function test abnormal. Gemtuzumab dosage: unknown. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN, CYTARABINE, LISINOPRIL, TERAZOSIN, FLUCONAZOLE, VANCOMYCIN, MEROPENEM, METOPROLOL SUCCINATE. Patient was hospitalized. Patient recovered.

Gemtuzumab Side Effects Report #4799898-7
Gemtuzumab side effect was reported by a Consumer or non-health professional from JAPAN on Sept 30, 2005. Female patient, 64 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, aspartate aminotransferase increased, blast cells present, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, cerebral haemorrhage, disseminated intravascular coagulation, gamma-glutamyltransferase increased, haematocrit decreased. Gemtuzumab dosage: 13.5 MG 1X PER 1 DAY INTRAVENOUS DRIP. During the same period patient was treated with MEROPEN, FUNGIZONE, VANCOMYCIN, MINOPHAGEN C, SOLCOSERYL, PRIMPERAN, FAMOTIDINE, VISCORIN. Patient died.


Gemtuzumab Side Effects Report #4866417-6
Gemtuzumab side effect was reported by a Consumer or non-health professional from JAPAN on Dec 13, 2005. Female patient, 64 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: activated partial thromboplastin time prolonged, alanine aminotransferase increased, aspartate aminotransferase increased, blast cell count increased, blood lactate dehydrogenase increased, c-reactive protein increased, cerebral haemorrhage, chills, gamma-glutamyltransferase increased. Gemtuzumab dosage: 13.5 MG 1X PER 1 DAY. During the same period patient was treated with MEROPEN, FUNGIZONE, VANCOMYCIN, MINOPHAGEN C, SOLCOSERYL, PRIMPERAN, FAMOTIDINE, VISCORIN. Patient died.

Gemtuzumab Side Effects Report #4845443-7
Gemtuzumab side effect was reported by a Consumer or non-health professional from AUSTRALIA on Nov 21, 2005. Male patient, 57 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, anxiety , blood alkaline phosphatase increased, blood lactate dehydrogenase increased, bone marrow failure, gamma-glutamyltransferase increased, haematocrit decreased, haemoglobin decreased, lymphocyte count decreased. Gemtuzumab dosage: unknown. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN, CYTARABINE, PHENERGAN, HYDROCORTISONE, PREDNISONE, ATENOLOL, FLUCONAZOLE, FOLIC ACID. Patient was hospitalized. Patient died.

Gemtuzumab Side Effects Report #4869556-9
Gemtuzumab side effect was reported by a Consumer or non-health professional from AUSTRALIA on Oct 15, 2002. Male patient, 57 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, anxiety , aspartate aminotransferase increased, blood alkaline phosphatase increased, blood lactate dehydrogenase increased, gamma-glutamyltransferase increased, haematocrit decreased, mood altered, platelet count decreased. Gemtuzumab dosage: 11.4 MG ONE TIME PER ONE DOSE INTRAVENOUS; SEE IMAGE. During the same period patient was treated with GEMTUZUMAB OZOGAMICIN, CYTARABINE, PHENERGAN, HYDROCORTISONE, PREDNISONE, ATENOLOL, FLUCONAZOLE, FOLIC ACID. Patient was hospitalized. Patient died.

Gemtuzumab Side Effects Report #4867042-3
Gemtuzumab side effect was reported by a Health Professional from NETHERLANDS on Mar 10, 2002. Male patient, 53 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: asthenia, blast cells present, blood lactate dehydrogenase increased, hypertension, hypotension, infection , pancytopenia, pneumonia , respiratory failure. Gemtuzumab dosage: CYCLE 1 (13-OCT-98) : CYCLE 2 CYCLE INTRAVENOUS; 2 (02-NOV-98) : 9 MG/M (2). During the same period patient was treated with CIPROXIN, DIFLUCAN, TAVEGIL. Patient was hospitalized. Patient died.

Gemtuzumab Side Effects Report #4867127-1
Gemtuzumab side effect was reported by a Physician from SPAIN on Mar 10, 2002. Male patient, 20 years of age, was diagnosed with acute myeloid leukaemia and was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: alanine aminotransferase increased, anaemia, anuria, ascites, aspartate aminotransferase increased, blood lactate dehydrogenase increased, condition aggravated, hypocalcaemia, liver disorder. Gemtuzumab dosage: 9 MG/M^2 1X PER 1 DOS INTRAVENOUS. During the same period patient was treated with CIPROFLOXACIN, FLUCONAZOLE. Patient was hospitalized. Patient died.


Gemtuzumab Side Effects Report #5055220-2
Gemtuzumab side effect was reported by a Consumer or non-health professional from GERMANY on July 05, 2006. Female patient, 70 years of age, was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: acute myocardial infarction, arrhythmia , blood lactate dehydrogenase increased, electrocardiogram st segment depression, septic shock, ventricular tachycardia. Gemtuzumab dosage: 12.18 MG. During the same period patient was treated with CYTARABINE, ETOPOSIDE, NOVANTRONE, RAMIPRIL. Patient was hospitalized. Patient died.

Gemtuzumab Side Effects Report #5055222-6
Gemtuzumab side effect was reported by a Consumer or non-health professional from GERMANY on July 05, 2006. Male patient, 70 years of age, was treated with Gemtuzumab. After drug was administered, patient experienced the following side effects: acute myocardial infarction, arrhythmia , blood lactate dehydrogenase increased, electrocardiogram st segment depression, septic shock, ventricular tachycardia. Gemtuzumab dosage: 12.18 MG. During the same period patient was treated with CYTARABINE, ETOPOSIDE, NOVANTRONE, RAMIPRIL. Patient was hospitalized. Patient died.